MARKET

RLAY

RLAY

Relay Therapeutics, Inc.
NASDAQ
8.43
+0.27
+3.31%
Opening 15:20 03/28 EDT
OPEN
8.11
PREV CLOSE
8.16
HIGH
8.43
LOW
7.99
VOLUME
296.29K
TURNOVER
0
52 WEEK HIGH
19.23
52 WEEK LOW
5.95
MARKET CAP
1.11B
P/E (TTM)
-3.0216
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at RLAY last week (0318-0322)?
Weekly Report · 3d ago
Strong Buy Rating for Relay Therapeutics Amid Pipeline Progress and Strategic Direction
TipRanks · 03/19 05:38
RSI Alert: Relay Therapeutics (RLAY) Now Oversold
NASDAQ · 03/18 15:56
Weekly Report: what happened at RLAY last week (0311-0315)?
Weekly Report · 03/18 10:11
Relay Therapeutics: Platform More Important Than Programs
Seeking Alpha · 03/13 06:50
RLAY Crosses Below Key Moving Average Level
NASDAQ · 03/11 15:49
Weekly Report: what happened at RLAY last week (0304-0308)?
Weekly Report · 03/11 10:09
Big Pharma patent cliffs seen fueling oncology M&A this year
Big Pharma patent cliffs seen fueling oncology M&A this year. Around $182B in revenue is at risk over the next four years due to patent expirations. Cantor Fitzgerald sees between five and 17 acquisition deals for oncologists in 2014. The global market for cancer drugs is expected to grow from $180B in 2022 to $323B in 2028.
Seeking Alpha · 03/10 17:08
More
About RLAY
Relay Therapeutics Inc. is a clinical-stage precision medicine company. The Company is focused on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The Company’s Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company’s lead product candidates, such as RLY-2608, Lirafugratinib (RLY-4008), and Migoprotafib (GDC-1971). RLY-2608 is an allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alphas (PI3Kα), inhibitor. RLY-4008, is a potent, selective, and oral small molecule inhibitor of FGFR2, a receptor tyrosine kinase that is frequently altered in certain cancers. GDC-1971 is an inhibitor of Src homology region 2 domain-containing phosphatase-2 (SHP2), as a monotherapy in patients with advanced or metastatic solid tumors.

Webull offers Relay Therapeutics Inc stock information, including NASDAQ: RLAY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RLAY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RLAY stock methods without spending real money on the virtual paper trading platform.